Profile of BCR-ABL Transcript Levels Based on Sokal Prognostic Score in Chronic Myeloid Leukemia Patients Treated with Imatinib
ABSTRACT: to elucidate the
pattern of molecular response assessed by logarithmic reduction in BCR-ABL transcription
levels based on Sokal prognostic score in chronic phase chronic myeloid
leukemia (CML) patients receiving Imatinib treatment. Methods: cross-sectional
study was conducted in the Hematologic Outpatient Clinic, Dr. Soetomo Hospital
Surabaya in all chronic phase CML patients from June 2008 to June 2012. Data on
subject characteristics (age and sex), complete blood count with differential
and spleen size were collected. Patients were stratifed according to Sokal
score at diagnosis. Real-time quantitative PCR (RT-qPCR) were used to monitor
BCR-ABL levels in patients who fulflled study. Proportion difference of
complete molecular response (MR) was analyzed by chi-square test, while
differences of BCR-ABL transcript level among Sokal prognostic scole subgroups
was analyzed by Kruskal-Wallis test. Results: 40 subjects fnished the study.
After 18 months of Imatinib treatment, the undetected BCR-ABL transcript level
(complete MR) were 7(70%), 8(66.7%), and 9(50%) in low-, intermediate-, and
high risk group patients, respectively (p=0.417). Although proportion of
subjects with complete MR is higher in sokal low risk group compared to in
sokal high risk groups (70% v.s. 50%), but this difference is not statistically
signifcant (p=0.557). Kruskal-Wallis test showed that there was no signifcant
difference of BCR-ABL transcript level among Sokal prognostic score subgroup
(p=0.734). Conclusion: there was no difference of BCR-ABL transcript level
among sokal prognostic score risk groups in chronic phase CML patients treated
with Imatinib.
Author: mi Ashariati, S.
Ugroseno
Journal Code: jpkedokterangg130258
